

The Evolving Treatment Paradigm of Hepatocellular Cancer

Strategies for Managed Care Pharmacists to Mitigate Costs

Monday, November 16, 2020 6:00 pm - 7:00 pm et

EDUCATIONAL OBJECTIVES

- Explore clinical data supporting the use of targeted and immunotherapies for the treatment of advanced hepatocellular carcinoma (HCC)
- Correlate how current and evolving treatment approaches for advanced HCC impact the cost of care
- Construct strategies to improve quality of care and limit financial toxicity for patients with advanced HCC through collaboration with the multidisciplinary team

Accreditation



Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-20-255-L01-P. The activity is available for CE credit on November 16, 2020.

Type of Activity

Application

Supporter Statement:

This activity is supported by an educational grant from BeiGene, Ltd

FACULTY



Laura R. Bobolts, PharmD, BCOP

Senior Vice President, Clinical Strategy and Growth Oncology Analytics, Inc. Clinical Affiliate Assistant Professor Nova Southeastern University College of Pharmacy Fort Lauderdale, Florida

Dr. Laura R. Bobolts is the Senior Vice President of Clinical Strategy and Growth at Oncology Analytics, Inc, focused on developing new products and innovating oncology utilization management services. Here she designed Oncology Pharmacy Consulting Services offered to health plans to surface tailored opportunities and design drug strategies supporting the most cost-effective approaches to high quality cancer care. She maintained clinical pathways supporting e-prior authorization for cancer treatments and associated supportive care. In this role she works closely with payers, discussing trends in cancer drug use, developing biosimilar strategies, and updating drug policies to help manage the rising costs of cancer care.

She graduated from Nova Southeastern University's College of Pharmacy where she teaches oncology pharmacotherapy and completed a residency at the James A. Haley Veterans' Hospital. She began her professional career at Moffitt Cancer Center, first specializing in malignant hematology, and later breast and gynecologic oncology. She established the role of the first clinical oncology pharmacist positioned in the Women's Oncology Clinic at Moffitt Cancer Center. She also practiced pediatric oncology at the Joe DiMaggio Children's Hospital prior to joining Oncology Analytics. She is a Board Certified Oncology Pharmacist (BCOP), a peer-reviewer for JAMA Oncology, published in Lancet Oncology.

Faculty disclosures will be provided prior to the presentation.

